



## **Miravo Healthcare™ to Host Investor Webcast on December 2, 2021 at 2:00 p.m. ET**

Mississauga, Ontario, Canada – November 18, 2021 – Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it will host an investor presentation webcast on Thursday, December 2, 2021 at 2:00 p.m. ET (11:00 a.m. PT).

During the webcast, Jesse Ledger, President & Chief Executive Officer and Mary-Jane Burkett, Vice President & Chief Financial Officer of Miravo will provide a PowerPoint presentation that will cover key areas of Miravo's business. During the presentation, investors will have an opportunity to ask questions through an interactive Q&A portal.

To access the webcast or to ask questions during the live event, please pre-register at the following link: [https://event.webcasts.com/starthere.jsp?ei=1495546&tp\\_key=8127b0e5a0](https://event.webcasts.com/starthere.jsp?ei=1495546&tp_key=8127b0e5a0).

An archived version of the webcast and presentation will be available on the Presentations & Webcasts page of the Company's website, <https://www.miravohealthcare.com/investors/presentations-webcasts/> following the event.

### **About Miravo Healthcare**

Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company's products target several therapeutic areas, including pain, allergy, and dermatology. The Company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo's head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company's manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit [www.miravohealthcare.com](http://www.miravohealthcare.com).

### **FOR MORE INFORMATION, PLEASE CONTACT:**

Investor Relations

Stefan Eftychiou  
905 326 1888 ext 60  
[stefan@bristolir.com](mailto:stefan@bristolir.com)